Zoetis Inc. (NYSE:ZTS) Shares Bought by Osprey Private Wealth LLC

Osprey Private Wealth LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,945 shares of the company’s stock after purchasing an additional 740 shares during the period. Zoetis makes up approximately 1.6% of Osprey Private Wealth LLC’s investment portfolio, making the stock its 28th largest holding. Osprey Private Wealth LLC’s holdings in Zoetis were worth $2,272,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Pensionfund Sabic grew its holdings in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after acquiring an additional 4,000 shares during the period. PFW Advisors LLC acquired a new position in Zoetis during the fourth quarter worth about $1,764,000. JPMorgan Chase & Co. grew its holdings in Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after acquiring an additional 279,092 shares during the period. Simplify Asset Management Inc. acquired a new position in Zoetis during the third quarter worth about $11,684,000. Finally, Nordea Investment Management AB grew its holdings in Zoetis by 38.3% during the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after acquiring an additional 572,511 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.2 %

Shares of Zoetis stock opened at $172.24 on Wednesday. The firm has a market cap of $77.71 billion, a price-to-earnings ratio of 32.38, a P/E/G ratio of 2.72 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The stock has a 50-day simple moving average of $169.48 and a 200-day simple moving average of $179.39.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company earned $1.36 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. On average, equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. This is an increase from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Analysts Set New Price Targets

ZTS has been the topic of a number of analyst reports. Morgan Stanley dropped their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. Finally, Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.